This site requires JavaScript and cookies to be enabled.

Help your patients
with ADHD switch
to Qelbree1

5 years,* several million prescriptions†—and counting—make Qelbree the
#1 prescribed branded nonstimulant ADHD treatment.1,2‡

*Pediatric indication approved in 2021.
†Source: IQVIA NPA data, as of March 31, 2026.
‡IQVIA data, as of May 2026.

Qelbree is a nonstimulant treatment option for patients struggling with ADHD symptoms1

Does your patient with ADHD still:


  •  Feel overwhelmed?3
  •  Act chronically disorganized?3
  •  Exhibit poor time management?3
  •  Struggle to manage daily tasks and activities?3
  •  Have trouble making or keeping friendships?3
  •  Lack self-motivation or
    self-management?3

Consider Qelbree—a nonstimulant that works1

Market data support that Qelbree is a versatile option for ADHD patients regardless of prior patient therapy§

HCP Real World Data
A young girl smiles and reaches for an adult's hand while climbing a playground ladder.
A young girl smiles and reaches for an adult's hand while climbing a playground ladder.

Patients who switched to Qelbree came from a variety of previous therapies2

49% switched to Qelbree from stimulants and 51% from nonstimulants.

Switching from stimulant ADHD medications to Qelbree

49% of patients who switched to Qelbree came from prior ADHD treatment with one of these stimulant sources2¶:

  •  Vyvanse®: 23%
  •  AMP ER: 16%
  •  MPH ER: 26%
  •  MPH IR: 14%
  •  AMP IR: 11%
  •  DEXMPH/Focalin®: 11%
  •  Other: 0%

 

Switching from other nonstimulant ADHD medications to Qelbree

51% of patients who switched to Qelbree came from prior ADHD treatment with one of these nonstimulant sources2¶:

  •  Atomoxetine/Strattera®: 74%
  •  Guanfacine/Intuniv®: 23%
  •  Other: 4%

 

§N=128,351 new-to-brand prescriptions. Source: IQVIA Xponent market dynamics data, R52W, as of April 24, 2026.
∥Previous ADHD treatment was defined as patients who switched to Qelbree or for whom Qelbree was added as a part of their treatment plan.
Percentages may not total 100% due to rounding.

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; AMP, mixed amphetamine salts; DEXMPH, dexmethylphenidate; ER, extended release; IR, immediate release; MPH, methylphenidate.

What your peers are saying about Qelbree

 

Days can be chaotic for many adult patients with ADHD. Qelbree offers full-day coverage and is proving to be a good option for many of my patients.

– Greg Mattingly, MD

 

I have developed confidence that Qelbree can help my ADHD patients to reach their treatment goals.

– Andrew Cutler, MD

 

Having a reliable nonstimulant option for the treatment of adults is very favorable in our practice.

– Derek Susalla, PA-C

Watch their video

 

The benefits for me using Qelbree are vast. I love that the indication starts from 6 years old and goes to adults—this medicine has a place in all of those age groups.

– Jo Hughes, PA-C, CAQ-PSY, DMSc

Watch their video

Discover more:

Qelbree dosing  Savings card  Request samples 

Stay informed

Get Qelbree email updates, savings information, and links to helpful resources for you and your patients.

Sign up 

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.

References:

1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc.
2. Data on file, Supernus Pharmaceuticals, Inc.
3. American Psychiatric Association. Attention-deficit/ hyperactivity disorder. In: Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text rev. American Psychiatric Association; 2022:68-77.

IMPORTANT SAFETY INFORMATION

INDICATION

Qelbree (viloxazine extended-release capsules) is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in [read more] patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all [read more] Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

  • Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
  • Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

  • Suicidal thoughts and behaviors: Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes
  • Heart rate, blood pressure increases: Qelbree can cause an increase in diastolic blood pressure and heart rate. Assess these measures prior to starting therapy, following increases in dosage, and periodically during therapy
  • Activation of mania or hypomania: Noradrenergic drugs may induce a manic or mixed episode in patients with bipolar disorder. Prior to initiating treatment with Qelbree, screen patients to determine if they are at risk for bipolar disorder. Screening should include a detailed psychiatric history, including a personal or family history of suicide, bipolar disorder, and depression 
  • Somnolence and fatigue: Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, due to potential somnolence (including sedation or lethargy) and fatigue, until they know how they will be affected by Qelbree 

ADVERSE REACTIONS

The most common adverse reactions (≥ 5% and at least twice the rate of placebo for any dose) in patients 6 to 17 years were somnolence, decreased appetite, fatigue, nausea, vomiting, insomnia, and irritability, and in adults, insomnia, headache, somnolence, fatigue, nausea, decreased appetite, dry mouth, and constipation. 

PREGNANCY

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Qelbree during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at 1-866-961-2388 or by visiting www.womensmentalhealth.org/preg. 

Please see full Prescribing Information, including Boxed Warning.